Innate Pharma S.A. (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. (NASDAQ:IPHA) saw a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 65,200 shares, a growth of 10.9% from the October 15th total of 58,800 shares. Based on an average daily volume of 8,400 shares, the short-interest ratio is currently 7.8 days.

Analysts Set New Price Targets

IPHA has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $11.50 price target on shares of Innate Pharma in a report on Tuesday, November 12th. Evercore ISI raised shares of Innate Pharma to a “strong-buy” rating in a research note on Monday, September 16th.

Innate Pharma Stock Up 6.3 %

NASDAQ:IPHA traded up $0.09 during trading hours on Monday, hitting $1.53. 41,648 shares of the stock were exchanged, compared to its average volume of 9,219. The company’s 50 day moving average is $2.02 and its two-hundred day moving average is $2.23. Innate Pharma has a twelve month low of $1.29 and a twelve month high of $3.15.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.